对狼疮性肾炎治疗药物的临床合理应用新认识

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (5): 570-575.

对狼疮性肾炎治疗药物的临床合理应用新认识

严尚学¹, 邓晓媚¹, 徐星铭², 魏伟¹

¹安徽医科大学临床药理研究所,抗炎免疫药物教育部重点实验室,合肥 230032,安徽;
²安徽医科大学第一附属医院肾内科,合肥 230022,安徽

收稿日期:2012-08-13 修回日期:2012-11-30 出版日期:2013-05-26 发布日期:2013-05-22
通讯作者: 魏伟,男,教授,研究方向:抗炎免疫药理学、临床药理学。Tel: 0551-5161209 E-mail:wwei@ahmu.edu.cn徐星铭,女,副教授,副主任医师,研究方向:肾脏疾病。Tel: 0551-2922111 E-mail: xxm2425@163.com
作者简介:严尚学,男,博士研究生,副研究员,研究方向:抗炎免疫药理学。Tel: 0551-5161208 E-mail: yan-shx@163.com
基金资助:
国家自然科学基金资助项目(No 30973543、81173075);安徽高校省级自然科学研究重点项目(KJ2011A177)

New insights of the reasonable application of clinical drugs on the treatment for lupus nephritis

YAN Shang-xue¹, DENG Xiao-mei¹, XU Xing-ming², WEI Wei¹

¹Institute of Clinical Pharmacology, Anhui Medical University,Key Laboratory of Immune Medicine(Anhui Medical University), Ministry of Education, Ministry of Education, Hefei 230032,Anhui, China;
²Department of Nephrology, the First Affilicated Hospital of Anhui Medical University,Hefei 230022,Anhui, China

Received:2012-08-13 Revised:2012-11-30 Online:2013-05-26 Published:2013-05-22

摘要/Abstract

摘要： 肾脏是系统性红斑狼疮最常受累的器官之一,狼疮性肾炎(Lupus nephritis, LN) 是患者死亡的主要原因。根据不同病理分型,LN的治疗一般分为诱导期治疗和缓解期治疗两个阶段。免疫抑制剂与激素联合用药是目前临床治疗的主要用药方案。随着现代医药技术的发展和对LN发病机制的深入探索,LN的治疗取得了长足性进展,患者生存率明显提高,现就LN治疗药物的临床合理应用新进展予以综述。

关键词: 狼疮性肾炎, 治疗药物, 合理应用

Abstract: Kidney damage remains one of the most devastating complications of systematic lupus erythematosus (SLE). Lupus nephritis(LN) is the major cause of morbidity and mortality in patients with SLE. The treatment protocol for LN is emphasized to use induction and maintenance therapies sequentially according to the pathological types. The combination of immunosuppressant and glucocorticoid therapy is the major project on clinical treatment for LN patients. With the development of modern medical technology and the deep explore of the pathogenic of LN, the treatment strategy of LN has been improved significantly and the survival of the patients has obviously increased. Herein the new insights about the treatment for LN are reviewed.

Key words: Lupus nephritis, Clinical drugs, Reasonable application

中图分类号:

R593.24⁺²

严尚学, 邓晓媚, 徐星铭, 魏伟. 对狼疮性肾炎治疗药物的临床合理应用新认识[J]. 中国临床药理学与治疗学, 2013, 18(5): 570-575.

YAN Shang-xue, DENG Xiao-mei, XU Xing-ming, WEI Wei. New insights of the reasonable application of clinical drugs on the treatment for lupus nephritis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 570-575.

参考文献

[1] Yokoyama H, Okuyama H, Yamaya H. Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians[J]. Clin Exp Nephrol, 2011,15(3):321-330.
[2] Yokoyama H, Okuyama H, Yamaya H. Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians[J]. Clin Exp Nephrol, 2011,15(3):321-330.
[3] Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients[J]. Medicine (Baltimore), 2003,82(5):299-308.
[4] American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines.Guidelines for referral and management of systemic lupus erythematosus in adults. [J]. Arthritis Rheum, 1999,42(9):1785-1796.
[5] Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis[J]. Arthritis Care Res, 2012,64(6):797-808.
[6] Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1982,25(11):1271-1277.
[7] Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus[J]. Lupus, 2004,13(11):857-860.
[8] Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004,65(2):521-530.
[9] Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited[J]. J Am Soc Nephrol, 2004,15(2):241-250.
[10] 中华医学会风湿病学分会. 系统性红斑狼疮诊断及治疗指南[J]. 中华风湿病学杂志, 2010,14(5):342-346
[11] Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years[J]. Kidney Int, 2007,71(6):491-495.
[12] Hiramatsu N, Kuroiwa T, Ikeuchi H, et al. Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions[J]. Rheumatology (Oxford) , 2008,47(5):702-727.
[13] Stratta P, Mesiano P, Campo A, et a1. Life expectancy of women with lupus nephritis now approaches that of the general population[J]. Int J Immunopathol Pharmaco1, 2009,22(4):1135-1141.
[14] Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis[J]. N Eng J Med, 2011,365(20):1886-1895.
[15] Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial[J]. Ann Rheum Dis, 2010,69(12):2083-2089.
[16] Tang Z, Yang G, Yu C, et al. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis[J]. Nephrology (Carlton), 2008, 13(8):702-707.
[17] Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis[J]. Kidney Int, 2010,77(2):152-160.
[18] Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus[J]. N Engl J Med, 1991,324(3):150-154.
[19] Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual[J].Arthritis Rheum, 2005,52(5):1473-1480.
[20] Pons-Estel GJ, Alarcon GS, McGwin G Jr, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort[J]. Arthritis Rheum, 2009,61(6):830-839.
[21] Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy[J]. Arthritis Rheum, 2006,54(11):3640-3647.
[22] Gordon C. Pregnancy and autoimmune diseases[J]. Best Pract Res Clin Rheumatol, 2004,18(3):359-379.
[23] Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study[J]. Mod Rheumatol, 2009, 19(6): 606-615.
[24] Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis[J]. Rheumatology, 2008, 47(11): 1678-1681.
[25] Uchida K, Asamiya Y, Takei T,et al. Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients[J]. Yakugaku Zasshi, 2010,130(1):113-118.
[26] Uchino A, Tsukamoto H, Nakashima H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria[J]. Clin Exp Rheumatol,2010 ,28(1):6-12.
[27] Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus[J]. Nephrol Dial Transplant, 2010,25(11):3586-3592.
[28] Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases[J]. Lupus, 2009,18(9):767-776.
[29] Landmark lupus approval opens door for next wave of drugs[J]. Nat Rev Drug Discov,2011,10(4): 243-245.
[30] Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011,377(9767):721-731.
[31] Dubey AK, Handu SS, Dubey S, et al. Belimumab: First targeted biological treatment for systemic lupus erythematosus[J]. J Pharmacol Pharmacother, 2011, 2(4): 317-319.
[32] Schroder JO, Zeuner RA. Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges[J]. Curr Drug Discov Technol, 2009,6(4):252-255.